Biopharmaceutical CMO & CRO Market

Biopharmaceutical CMO & CRO Market Size, Share & Trends Analysis
Report and Segment Forecast, 2025| Grand View Research, Inc
“The global biopharmaceutical CMO & CRO market size was estimated at 22.47
billion in 2018 and is projected to expand at a CAGR of 7.7% during the forecast
period.”
The global Biopharmaceutical Cmo & Cro Market size is expected to reach USD 37.8 billion by 2025, at a CAGR
of 7.7%, according to a new report by Grand View Research, Inc. The market is significantly driven by the
growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has
become a cost-saving strategy for small to medium sized biomanufacturers, as it helps eliminate the need for
establishing expensive specialized facilities or hiring and training personnel.
The decline in R&D productivity and increased development costs has resulted in high pressure on
biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has
created lucrative opportunities for the Contract Manufacturing Organizations (CMOs) and Contract Research
Organizations (CROs) to accelerate their business operations.
Robustness of venture capital investments is one of the important supportive factors that have created growth
opportunities for CMOs. Venture capital funds are considered more reliable than public equity. Increasing
availability of venture funds for life sciences is expected to further bolster the growth of CMOs. However, these
CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology
companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process inhouse.
Mammalian cell line-based bioproduction systems held the largest market share in terms of revenue in 2018.
Factors responsible for this estimated share include growth in mammalian system titers and yields. CMOs are
engaged in standardizing their mammalian systems, thereby driving the revenue growth of the segment.
Follow Us:
Contract research service is anticipated to be the fastest growing segment over the forecast period, attributed
to increasing investment in research programs for development of novel therapeutics. The CMOs are majorly
benefitted by the continuous market expansion of biologics.
Several biopharma companies from U.S. are considering Asian countries for development of pharma products.
This is primarily due to the growing costs of R&D in their home country and the presence of low-cost
production facilities and cheap labor in Asian countries. The key players are also involved in establishing
mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.
To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-cmo-cro-market
Further key findings from the report suggest:

Mammalian cell line-based bioproduction system accounted for the largest market share in terms of
revenue in 2018

Plant-based expression systems are developed and explored as a cost-effective alternative for the
production of large molecules

Contract manufacturing services accounted for the largest market share owing to the presence of wide
range of services from cell line development to final packaging of the product

In recent times, biologics manufacturing is becoming more specialized, as a result, CMOs have become
an integral part of the biologics production strategies of clients, leading to biologics gaining a large
share of the biopharmaceutical CMO & CRO market

North America biopharmaceutical research industry is recognized as a leader in biopharmaceutical
innovations, thereby resulting in the large share of this region

Some key CMOs are Lonza; Boehringer Ingelheim GmbH; Patheon; Samsung BioLogics; FUJIFILM
Diosynth Biotechnologies U.S.A., Inc.
Grand View Research has segmented the global biopharmaceutical CMO & CRO market on the basis of source,
service, product, and region:
Biopharmaceutical CMO & CRO Source Outlook (Revenue, USD Million, 2014 - 2025)

Mammalian

Non-mammalian
Biopharmaceutical CMO & CRO Service Outlook (Revenue, USD Million, 2014 - 2025)

Contract Manufacturing
Follow Us:
o

Process Development
o
Downstream
o
Upstream
o
Fill & Finish Operations
o
Analytical & QC studies
o
Packaging
Contract Research
o
Oncology
o
Inflammation & Immunology
o
Cardiology
o
Neuroscience
o
Others
Biopharmaceutical CMO & CRO Product Outlook (Revenue, USD Million, 2014 - 2025)


Biologics
o
Monoclonal Antibodies (MAbs)
o
Recombinant Proteins
o
Vaccines
o
Antisense, RNAi, & Molecular Therapy
o
Others
Biosimilars
Biopharmaceutical CMO & CRO Regional Outlook (Revenue, USD Million, 2014 - 2025)


North America
o
U.S.
o
Canada
Europe
Follow Us:


o
Germany
o
France
Asia Pacific
o
China
o
India
Latin America
o

Brazil
Middle East & Africa
o
Follow Us:
South Africa
Table of Content of Biopharmaceutical CMO & CRO Market
Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Biopharmaceutical CMO & CRO Market Outlook, 2014 - 2025
2.2 Biopharmaceutical CMO & CRO Market : Segment Outlook, 2014 - 2025
2.3 Biopharmaceutical CMO & CRO Market : Competitive Insights
Chapter 3 Biopharmaceutical CMO & CRO Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping, 2018
3.3 Product Pipeline Analysis, by Stage
3.4 Cost Structure Analysis
3.5 User Perspective Analysis
3.5.1. Consumer behavior analysis
3.5.2. Market influencer analysis
3.6 Procedure Cost Analysis/Breakdown
3.7 List of Key End-users By Region, By Service Type, By Country
3.8 Technology Overview
3.9.3. Technology timeline
Follow Us:
3.9 Regulatory Framework
3.9.1. Reimbursement framework
3.9.2. Standards & compliances
3.10 Biopharmaceutical CMO & CRO Market - Market Dynamics
3.10.1 Market driver analysis
3.10.1.1 Rising investment by CMOs for capacity expansion
3.10.1.2 Commercial success of biopharmaceuticals and consequent increased demand for the
biopharmaceuticals
3.10.1.3 Robust biopharmaceuticals pipeline
3.10.1.4 Cost and time saving benefits offered by contract services
3.10.2 Market restraint analysis
3.10.2.1 Limited outsourcing amongst well-stablished biopharmaceutical manufacturer
3.10.3 Market challenges analysis
3.10.3.1 Well established players are expanding their in-house biologic development procedures
3.11 Biopharmaceutical CMO & CRO Market Analysis Tools
3.11.1 Industry Analysis - Porter’s
3.11.1.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes
to the low supplier power
3.11.1.2 Buyer Power: Fragmaneted nature of biopharmaceutical industry led to moderate
bargaining power of buyers
3.11.1.3 Substitution Threat: High due to presence of large number big pharma companies
3.11.1.4 New Entrants Threat: Presence of established players coupled with need of adequate
capacity results in moderate threat of new entrants
3.11.1.5 Competitive rivalry: High competitive rivalry amomg key players owing to significant
number of merger & acquisitions and strategic alliances among biopharmaceutical developers
3.11.2 PESTEL analysis
3.11.2.1 Political landscape
3.11.2.2 Environmental landscape
3.11.2.3 Social landscape
3.11.2.4 Technology landscape
3.11.2.5 Legal landscape
Follow Us:
3.11.3 Major deals & strategic alliances analysis
3.11.3.1 Joint ventures
3.11.3.2 Mergers & acquisitions
3.11.3.3 Licensing & partnership
3.11.3.4 Technology collaborations
3.11.3.5 Strategic divestments
3.11.4 Market entry strategies
3.11.5 Case studies
3.12 Trends in Biopharmaceutical Industry
3.13 R&D Landscape of Biopharmaceuticals
3.14 Customer Relationship Management in Contract Manufacturing
3.14.1 Selection process of CMO
3.14.2 Operations and quality oversight of CMOs
Chapter 4 Biopharmaceutical CMO & CRO Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Company market share/ranking by region
4.4.3 Competitive dashboard analysis
4.4.4 Market differentiators
4.4.5 Synergy analysis: Major deals & strategic alliances
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Funding outlook
4.5.3 Regional network map
4.5.4 Company market position analysis
Follow Us:
4.5.5 Supplier Ranking
Chapter 5 Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Source Market Share Analysis, 2018 & 2025
5.3 Biopharmaceuticals CMO & CRO Market: Source Movement Analysis, 2018 & 2025
5.4 Global Biopharmaceuticals CMO & CRO Market, by Source, 2014 to 2025
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
5.5.1 Mammalian source
5.5.1.1 Global mammalian source market, 2014 - 2025 (USD Million)
5.5.2 Non-mammalian Source
5.5.2.1 Global non-mammalian source market, 2014 - 2025 (USD
5.6 Biopharmaceuticals CMO & CRO Source Market, by Product, 2014 to 2025
Chapter 6 Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Service Type Market Share Analysis, 2018 & 2025
6.3 Biopharmaceuticals CMO & CRO Market: Service Type Movement Analysis, 2018 & 2025
6.4. Global Biopharmaceuticals CMO & CRO Market, by Service Type, 2014 to 2025
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
6.5.1 Contract manufacturing, by service
6.5.1.1 Global contract manufacturing market, 2014 - 2025 (USD Million)
6.5.1.2 Process development
6.5.1.2.1 Global process development market, 2014 - 2025 (USD Million)
6.5.1.2.2 Downstream processing
6.5.1.2.2.1 Global downstream processing market, 2014 - 2025 (USD Million)
6.5.1.2.3 Upstream processing
6.5.1.2.3.1 Global upstream processing market, 2014 - 2025 (USD Million)
6.5.1.3 Process development
6.5.1.3.1 Global process development market, 2014 - 2025 (USD Million)
6.5.1.4 Fill & finish operations
6.5.1.4.1 Global fill & finish operations market, 2014 - 2025 (USD Million)
6.5.1.5 Analytical & QC testing
Follow Us:
6.5.1.5.1 Global analytical & QC testing market, 2014 - 2025 (USD Million)
6.5.1.6 Packaging
6.5.1.6.1 Global contract packaging market, 2014 - 2025 (USD Million)
6.5.2 Contract research
6.5.2.1 Global contract research market, 2014 - 2025 (USD Million)
6.5.2.2 Oncology
6.5.1.2.1 Global oncology market, 2014 - 2025 (USD Million)
6.5.2.3 Inflammation & immunology
6.5.2.3.1 Global inflammation & immunology market, 2014 - 2025 (USD Million)
6.5.2.4 Cardiology
6.5.2.4.1 Global cardiology market, 2014 - 2025 (USD Million)
6.5.2.5 Neuroscience
6.5.1.5.1 Global neuroscience market, 2014 - 2025 (USD Million)
6.5.2.6 Others
6.5.1.6.1 Global other CRO services market, 2014 - 2025 (USD Million)
Chapter 7 Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Product Market Share Analysis, 2018 & 2025
7.3 Biopharmaceuticals CMO & CRO Market: Product Movement Analysis, 2018 & 2025
7.4. Global Biopharmaceuticals CMO & CRO Market, by Product, 2014 to 2025
7.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
7.5.1 Biologics
7.5.1.1 Global biologics market, 2014 - 2025 (USD Million)
7.5.1.2 Monoclonal antibodies
7.5.1.2.1 Global monoclonal antibodies market, 2014 - 2025 (USD Million)
7.5.1.3 Recombinant proteins
7.5.1.3.1 Global recombinant proteins market, 2014 - 2025 (USD Million)
7.5.1.4 Vaccines
7.5.1.4.1 Global vaccines market, 2014 - 2025 (USD Million)
7.5.1.5 Antisense, RNAi, & molecular therapy
7.5.1.5.1 Global antisense, RNAi, & molecular therapy market, 2014 - 2025 (USD Million)
Follow Us:
7.5.1.6 Others
7.5.1.7.1 Global other product market, 2014 - 2025 (USD Million)
7.5.2 Biosimilars
7.5.2.1 Global biosimilars market, 2014 - 2025 (USD Million)
Chapter 8 Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Source, Service
Type, & Product
8.1 Biopharmaceuticals CMO & CRO Market Share by Region, 2018 & 2025
8.2 Regional Market Share and Leading Players, 2018
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa
8.3 North America
8.3.1 North America biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.3.2.2 U.S. biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.3.2.3 U.S. biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.3.3 Canada
8.3.3.1 Canada biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.3.3.2 Canada biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.3.3.3 Canada biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.4 Europe
8.4.1 Europe biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.4.2 Germany
8.4.2.1 Germany biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.4.2.2 Germany biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.4.2.3 Germany biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.4.3 France
8.4.3.1 France biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
Follow Us:
8.4.3.2 France biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.4.3.3 France biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.5.2 China
8.5.2.1 China biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.5.2.2 China biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.5.2.3 China biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.5.3 India
8.5.3.1 India biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.5.3.2 India biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.5.3.3 India biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.6 Latin America
8.6.1 Latin America biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.6.2.2 Brazil biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD Million)
8.6.2.3 Brazil biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
8.7 Middle East & Africa (MEA)
8.7.1 Middle East & Africa biopharmaceuticals CMO & CRO market, 2014 - 2025 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa biopharmaceuticals CMO & CRO market, by source, 2014 - 2025 (USD Million)
8.7.2.2 South Africa biopharmaceuticals CMO & CRO market, by service type, 2014 - 2025 (USD
Million)
8.7.2.3 South Africa biopharmaceuticals CMO & CRO market, by product, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
9.1.1 Boehringer Ingelheim GmbH
9.1.1.1 Company overview
Follow Us:
9.1.1.2 Financial performance
9.1.1.3 Product benchmarking
9.1.1.4 Strategic initiatives
9.1.2 Lonza
9.1.2.1 Company overview
9.1.2.2 Financial performance
9.1.2.3 Product benchmarking
9.1.2.4 Strategic initiatives
9.1.3 Inno Biologics Sdn Bhd
9.1.3.1 Company overview
9.1.3.2 Financial performance
9.1.3.3 Product benchmarking
9.1.3.4 Strategic initiatives
9.1.4 Rentschler Biotechnologie SE
9.1.4.1 Company overview
9.1.4.2 Financial performance
9.1.4.3 Product benchmarking
9.1.4.4 Strategic initiatives
9.1.5 JRS PHARMA
9.1.5.1 Company overview
9.1.5.1.1 CELONIC AG
9.1.5.2 Financial performance
9.1.5.2.1 Financial performance
9.1.5.3 Product benchmarking
9.1.5.4 Strategic initiatives
9.1.6 BIOMEVA GmbH
9.1.6.1 Company overview
9.1.6.2 Financial performance
9.1.6.3 Product benchmarking
9.1.6.4 Strategic initiatives
9.1.7 ProBioGen AG
Follow Us:
9.1.7.1 Company overview
9.1.7.2 Financial performance
9.1.7.3 Product benchmarking
9.1.7.4 Strategic initiatives
9.3.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
9.3.8.1 Company overview
9.3.8.2 Financial performance
9.3.8.3 Product benchmarking
9.3.8.4 Strategic initiatives
9.3.9 TOYOBO CO., LTD.
9.3.9.1 Company overview
9.3.9.2 Financial performance
9.3.9.3 Product benchmarking
9.3.9.4 Strategic initiatives
9.3.10 Samsung BioLogics
9.3.10.1 Company overview
9.3.10.2 Financial performance
9.3.10.3 Product benchmarking
9.3.10.4 Strategic initiatives
9.3.11 Thermo Fisher Scientific Inc.(Patheon)
9.3.11.1 Company overview
9.3.11.1.1 DPx
9.3.11.2 Financial performance
9.3.11.3 Product benchmarking
9.3.11.4 Strategic initiatives
9.3.12 AGC Biologics (CMC Biologics)
9.3.12.1 Company overview
9.3.12.2 Financial performance
9.3.12.3 Product benchmarking
9.3.12.4 Strategic initiatives
9.3.13 Binex Co., Ltd.
Follow Us:
9.3.13.1 Company overview
9.3.13.2 Financial performance
9.3.13.3 Product benchmarking
9.3.13.4 Strategic initiatives
9.3.14 WuXi Biologics
9.3.14.1 Company overview
9.3.14.2 Financial performance
9.3.14.3 Product benchmarking
9.3.14.4 Strategic initiatives
9.3.15 AbbVie, Inc.
9.3.15.1 Company overview
9.3.15.2 Financial performance
9.3.15.3 Product benchmarking
9.3.15.4 Strategic initiatives
9.3.16 Charles River Laboratories International, Inc
9.3.16.1 Company overview
9.3.16.2 Financial performance
9.3.16.3 Product benchmarking
9.3.16.4 Strategic initiatives
9.3.17 ICON plc
9.3.17.1 Company overview
9.3.17.2 Financial performance
9.3.17.3 Product benchmarking
9.3.17.4 Strategic initiatives
9.3.18 Pharmaceutical Product Development, LLC
9.3.18.1 Company overview
9.3.18.2 Financial performance
9.3.18.3 Product benchmarking
9.3.18.4 Strategic initiatives
9.3.19 Laboratory Corporation of America Holdings
9.3.19.1 Company overview
Follow Us:
9.3.19.2 Financial performance
9.3.19.3 Product benchmarking
9.3.19.4 Strategic initiatives
9.3.20 PAREXEL International Corporation
9.3.20.1 Company overview
9.3.20.2 Financial performance
9.3.20.3 Product benchmarking
9.3.20.4 Strategic initiatives
9.3.21 PRA Health Sciences
9.3.21.1 Company overview
9.3.21.2 Financial performance
9.3.21.3 Product benchmarking
9.3.21.4 Strategic initiatives
9.4 List of Companies
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The global biopharmaceutical cmo & cro market size is expected to reach USD 37.8 billion by 2025, at a CAGR of 7.7%, according to a new report by Grand View Research, Inc.

Download Report